Pfizer partners with startup Flagship valued at US$7 BillionJulu 18, 2023 - "Pfizer and Flagship will explore up to 10 single-asset \start-up programs, which Pfizer will fund and have the option to acquire. Flagship and its companies will be eligible to receive up to $700 million in milestones and royalties for each program that hits the market, giving Tuesday’s deal a maximum potential value of $7 billion."
"The collaboration will leverage Flagship’s ecosystem of biotechnology platforms (bio-platforms) ....."
This partnership indicates that Pfizer, like other Big Pharma companies are facing a looming patent cliff and ar seeking ways to fill their product pipelines to off-set the loss of revenue from their former blockbuster products. As described earlier, M&A valuations for late-state clinical stage companies developing biologicals are at premium pricing, and have become very competitive assets to acquire, particularly in immuno-ocology products in the treatment of multiple cancers.
https://www.biospace.com/article/pfizer-inks-potential-7b-deal-with-flagship-to-deepen-pipeline/
[ONCY's late-stage phase 3 bio-platform in pelareorep addresses multiple unmet medical needs in the sought after oncology market space and is fairly valued for an M&A deal at between US$10 Billion to US$15 Billion.]